Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MYRX's Cash to Debt is ranked higher than
88% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYRX: No Debt )
MYRX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
MYRX's Interest Coverage is ranked higher than
78% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. MYRX: No Debt )
MYRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 1
Z-Score: -115.90
M-Score: -0.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -999.23
MYRX's ROE (%) is ranked lower than
61% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYRX: -999.23 )
MYRX' s 10-Year ROE (%) Range
Min: -999.23   Max: -30.74
Current: -999.23

-999.23
-30.74
ROA (%) -939.45
MYRX's ROA (%) is ranked lower than
61% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MYRX: -939.45 )
MYRX' s 10-Year ROA (%) Range
Min: -939.45   Max: -30.02
Current: -939.45

-939.45
-30.02
EBITDA Growth (%) -41.10
MYRX's EBITDA Growth (%) is ranked lower than
55% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYRX: -41.10 )
MYRX' s 10-Year EBITDA Growth (%) Range
Min: -41.1   Max: 9.1
Current: -41.1

-41.1
9.1
EPS Growth (%) -41.10
MYRX's EPS Growth (%) is ranked lower than
54% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MYRX: -41.10 )
MYRX' s 10-Year EPS Growth (%) Range
Min: -41.1   Max: 2.1
Current: -41.1

-41.1
2.1
» MYRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MYRX Guru Trades in

MYRX Guru Trades in

Q4 2012

MYRX Guru Trades in Q4 2012

Jim Simons 421,106 sh (+11.94%)
Murray Stahl 74,000 sh (unchged)
John Rogers Sold Out
Jean-Marie Eveillard Sold Out
» More
Q1 2013

MYRX Guru Trades in Q1 2013

Murray Stahl Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MYRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 Sold Out 0.03%$2.34 - $2.81 $ 0.18-93%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.00
MYRX's P/B is ranked lower than
60% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. MYRX: 6.00 )
MYRX' s 10-Year P/B Range
Min: 0.01   Max: 0.89
Current: 6

0.01
0.89
EV-to-EBIT -0.42
MYRX's EV-to-EBIT is ranked higher than
92% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. MYRX: -0.42 )
MYRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.00
MYRX's Price/Net Cash is ranked higher than
85% of the 214 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.10 vs. MYRX: 6.00 )
MYRX' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 2.5
Current: 6

0.68
2.5
Price/Net Current Asset Value 6.00
MYRX's Price/Net Current Asset Value is ranked higher than
80% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. MYRX: 6.00 )
MYRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.68   Max: 2.5
Current: 6

0.68
2.5
Price/Tangible Book 6.00
MYRX's Price/Tangible Book is ranked higher than
53% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. MYRX: 6.00 )
MYRX' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 2.5
Current: 6

0.59
2.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:R9M.Germany
Myrexis, Inc., was incorporated as Myriad Pharmaceuticals, Inc. in Delaware in January 2009 as a new, wholly owned subsidiary of Myriad Genetics, Inc., in order to effect the separation and spin-off of Myriad Genetics' research and drug development businesses as a stand-alone, independent, publicly traded company. In connection with the formation of this new subsidiary, Myriad Genetics' existing subsidiary, Myriad Pharmaceuticals, Inc., changed its corporate name to Myriad Therapeutics, Inc. Effective July 1, 2010, the Company changed its name from Myriad Pharmaceuticals, Inc. to Myrexis, Inc. The Company is engaged in evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide